At Enlivity, we deliver over-the-counter products made specifically to relieve side effects in the digestive system of patients going through cancer treatment. We use controlled release and targeted delivery methods to improve nutrient absorption along the gastrointestinal (GI) tract and partner with leading researchers and institutions to bring science-based nutrient solutions that result in better patient outcomes.


For patients with oral mucositis or esophagitis

Our first product, Healios, is a dietary supplement formulated by hematologist-oncologist Dr. Peter Anderson, MD, Ph.D. for patients with oral mucositis or esophagitis. Healios helps promote and maintain the health of the epithelial cells and mucosal tissues of the GI tract, particularly the mouth, throat, and esophagus. It contains a glutamine-disaccharide complex that increases glutamine uptake in the mucosal cells at risk of injury. 


The benefits of supplementing with nutrients found in Healios have been clinically demonstrated. Preliminary research found the unique formulation of glutamine with a blend of synergistic ingredients increased glutamine absorption by a factor of over 100 times – at the intended site of the mucosal lining. The concept has been tested in cancer patients in one pilot study and three larger randomized placebo, double-blind trials.

Research on Glutamine

Oral glutamine supplementation can reduce the severity and duration of oral mucositis in cancer patients. Below is supporting research.

  • A systematic review of clinical trials found glutamine reduced the severity and duration of oral mucositis by (i) inhibiting the production of pro-inflammatory cytokines, and (ii) meeting the demands of mucosal tissue during wound healing. However, because glutamine is only moderately soluble in water, and undergoes non-enzymatic degradation in the stomach, its bioavailability is limited, when administered orally or parenterally. Review Paper: Sayles et al, Nutrition in Clin Practice, 2016; 31[2]:171.
  • A randomized, prospective case-control study (adult head and neck cancer patients undergoing radiation therapy) demonstrated grades 3 and 4 mucositis were observed significantly less in patients receiving glutamine than in the control group. Research Paper: Chattopadhyay et al, South Asian J of Cancer, 2014; [3]1:8-12.
  • A double-blind, randomized, placebo-controlled study (pediatric patients undergoing hematopoietic stem cell transplantation) showed oral supplementation with glutamine significantly decreased the severity of oral mucositis.        Research Paper:  Aquino et al, Bone Marrow Transplantation, 2005; [36]:611-16.
  • A randomized, double-blind, crossover trial in cancer patients (adults & children) receiving chemotherapy found a low dose oral glutamine supplementation during & after chemotherapy significantly reduced both the duration & severity of chemotherapy-associated stomatitis. Research Paper: Anderson et al, Cancer, 1998;83:1433-9.
  • An early pilot study (non-randomized, adult cancer patients) demonstrated oral supplementation with glutamine significantly decreased the severity of chemotherapy-induced stomatitis, an important cause of morbidity in the treatment of patients with cancer.   Research Paper:  Skubitz et al, J Lab Clin Med, 1996; 127[2]:223-8.

Glutamine powder, when combined with mono- or di-saccharides then mixed with liquid to form a suspension, significantly increases glutamine absorption in the tissues that line the mouth, throat, and esophagus, among cancer patients receiving chemotherapy. Below is supporting research.

  • A clinical study found when glutamine is complexed with a mono- or di-saccharide, the mucosal absorption of glutamine was shown to increase by more than 1,000 times. The authors conclude the efficacy and safety of a glutamine powder in an oral suspension was shown for the prevention and treatment of oral mucositis in patients receiving cancer chemotherapy.  Clinical Study: Peterson et al, Cancer, 2007; 109:322-31

Preliminary research suggests trehalose, a non-cariogenic disaccharide, does not affect plasma insulin levels and may have anti-inflammatory and antioxidant benefits. Below is supporting research.

Research on Oral Mucositis

Oral mucositis can lead to negative clinical outcomes resulting in reduced quality of life for patients. Below is supporting research.

  • The pathogenesis of oral mucositis is multifactorial and complex and can negatively affect nutrition and quality of life of patients undergoing cancer treatment, sometimes leading to a dose-limiting complication of therapy.  Review Paper:  Lalla et al, Dent Clin North Am, 2008; 52(1):61-75.
  • A multinational, prospective study of patient-reported outcomes, showed virtually all head and neck patients undergoing radiation treatment, with or without chemotherapy, developed mouth and throat sores of a sufficient severity that reduced quality of life (QOL) and required analgesics, which provided inadequate relief.  Research Paper: Elting et al, Cancer, 2008; 113[10]:2704-13.

Oral mucositis increases costs of care among cancer patients undergoing treatment. Below is supporting research.

  • A review paper showed the side effects of cancer treatments, particularly those affecting the gastrointestinal tract (oral mucositis, diarrhea, nausea and vomiting) had significant clinical and economic costs associated with primary cancer therapy, largely attributable to increased hospitalization rates and lengths of hospital stay.  Review Paper:  Carlotto et al, PharmacoEconomics, 2013; 31:753-766.
  • A retrospective study among patients with head and neck cancer and non-small lung cancer who received radio-chemotherapy found medical costs were greater for those who developed severe mucositis/ pharyngitis, than for those who did not.  Research Paper:  Nonzee et al, Cancer, 2008; 113[6]:1446-52.
  • Chemotherapy- and radiation-induced oral mucositis has been shown to have a significant economic impact due to costs associated with pain management, liquid diet supplements, gastrostomy tube placement or total parenteral nutrition and management of secondary infections and hospitalizations.  Review Paper:  Lalla et al, Dent Clin North Am, 2008; 52(1):61-75.

Management of oral mucositis has primarily focused on palliative care, although new therapeutic solutions are being studied in context of current evidence-based clinical management guidelines. Below is supporting research.

  • Current clinical management of oral mucositis is largely focused on palliative measures such as pain management, nutritional support and maintenance of good oral hygiene. However, this paper reviewed several promising therapeutic agents in various stages of clinical development for the management of oral mucositis, in the context of recently updated evidence-based clinical management guidelines.           Review Paper:  Lalla et al, Dent Clin North Am, 2008; 52(1):61-75.

Research on Malnutrition

Early nutrition intervention among cancer patients going through treatment can improve treatment completion and reduce unplanned hospitalizations. Below is supporting research.

  • A retrospective study of head and neck cancer adult patients going through chemoradiotherapy found early nutrition intervention resulted in improved treatment tolerance and fewer hospital admissions, compared to those who did not receive early nutrition intervention.  Research Paper:  Paccagnella et al, Support Care Cancer, 2010; 18:837-845.
  • A retrospective study showed early nutrition intervention according to a Nutrition Pathway protocol, had a significant positive affect on nutritional status, improved treatment tolerance/completion rates and fewer unplanned hospital admissions during chemoradiation among esophageal cancer patients, compared to those who did not get early nutrition intervention.  Research Paper:  Odelli et al, Clinical Oncology, 2005; 17:639-645.

Using Healios®

Healios is an easy-to-use swish and swallow solution that can be a part of a supportive care plan before, during, and after cancer treatment.
It comes packaged as a flavored powder that when mixed with water creates an easy-to-swallow nutrient suspension.

  • Mix 1 scoop

    with 25-100ml of water using the included measuring bottle.

  • Swish in the mouth

    for 10 seconds and then swallow.

  • Take twice per day:

    once in the morning and once at bedtime. For best results, take with food or after a meal.

Healios® for Hospitals and Cancer Treatment Centers

Contact us to request trial units and detailed information

Healios can help improve patient outcomes and reduce healthcare resource utilization. We are able to offer a limited number of units to healthcare providers who would like to try Healios with their patients before purchasing or recommending. If you are interested in trying Healios or would like to receive more information including wholesale pricing, please fill out the form below and we will get back to you within 24hrs.

If you are a patient, you can order Healios directly through our site or you can contact us through our patient form.